Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00388427 · ClinicalTrials.gov registry record · Phase 1
Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies
A Phase 1 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT00388427 is a Phase 1 study that has completed, run by University of Pittsburgh. The registered enrollment target is 31 participants.
The verdict
NCT00388427, a Phase 1 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is an open-label, safety study of cetuximab and differing dose levels of dasatinib in adult patients with advanced solid malignancies. Cetuximab will be administered as an intravenous infusion weekly. Dasatinib will be taken orally, once a day, on a continuous schedule at differing dose levels. The primary objective of this study is to determine the toxicities and the maximum tolerated doses of dasatinib when combined with cetuximab for the treatment of advanced solid tumors.
Interventions
- DRUG Dasatinib (BMS-354825)
- DRUG Cetuximab (Erbitux, C225)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2007-06 |
| Est. Completion | 2013-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00388427
The ClinicalTrials.gov registry entry for NCT00388427 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dasatinib (BMS-354825) is the first listed.
NCT00388427 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00388427 about?
NCT00388427 is a clinical study titled "Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies". This is an open-label, safety study of cetuximab and differing dose levels of dasatinib in adult patients with advanced solid malignancies. Cetuximab will be administered as an intravenous infusion weekly. Dasatinib will be taken orally, once a day, on a continuous schedule at differing dose levels....
What is the current status of trial NCT00388427?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2007-06. Estimated completion is 2013-02.
What interventions are being tested in trial NCT00388427?
The interventions under investigation include: Dasatinib (BMS-354825) (DRUG), Cetuximab (Erbitux, C225) (DRUG).
Who is sponsoring clinical trial NCT00388427?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.